Neuropeptide S (NPS) variants modify the signaling and risk effects of NPS Receptor 1 (NPSR1) variants in asthma

Nathalie Acevedo1☯, Sini Ezer2☯, Simon Kebede Merid3, Vincent D. Gaertner4, Cilla Söderhäll5,6, Mauro D’Amato7,8, Michael Kabesch4, Erik Melen3,9, Juha Kere2,5*, Ville Pulkkinen10

1 Department of Clinical Science and Education, Karolinska Institutet, and Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, 2 Research Programs Unit, Program for Molecular Neurology, University of Helsinki, and Folkhälsan Institute of Genetics, Helsinki, Finland, 3 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Department of Pediatric Pneumology and Allergy, University Children’s Hospital’s Regensburg (KUNO), Regensburg, Germany, 5 Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden, 6 Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden, 7 BioDonostia Health Research Institute and IKERBASQUE, Basque Foundation for Science, San Sebastian Spain, 8 Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 9 Sachs’ Children’s Hospital, Stockholm, Sweden, 10 Heart and Lung Center, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Hospital, 00014 University of Helsinki, Helsinki, Finland

☯ These authors contributed equally to this work.
* juha.kere@ki.se

Abstract

Single nucleotide polymorphisms (SNPs) close to the gain-of-function substitution, Asn(107)Ile (rs324981, A>T), in Neuropeptide S Receptor 1 (NPSR1) have been associated with asthma. Furthermore, a functional SNP (rs4751440, G>C) in Neuropeptide S (NPS) encodes a Val(6)Leu substitution on the mature peptide that results in reduced bioactivity. We sought to examine the effects of different combinations of these NPS and NPSR1 variants on downstream signaling and genetic risk of asthma. In transfected cells, the magnitude of NPSR1-induced activation of cAMP/PKA signal transduction pathways and downstream gene expression was dependent on the combination of the NPS and NPSR1 variants with NPS-Val(6)/NPSR1-Ile(107) resulting in strongest and NPS-Leu(6)/NPSR1-Asn(107) in weakest effects, respectively. One or two copies of the NPS-Leu(6) (rs4751440) were associated with physician-diagnosed childhood asthma (OR: 0.67, 95%CI 0.49–0.92, p = 0.01) and together with two other linked NPS variants (rs1931704 and rs10830123) formed a protective haplotype (p = 0.008) in the Swedish birth cohort BAMSE (2033 children). NPS rs10830123 showed epistasis with NPSR1 rs324981 encoding Asn(107)Ile (p = 0.009) in BAMSE and with the linked NPSR1 rs17199659 (p = 0.005) in the German MAGIC/ISACC II cohort (1454 children). In conclusion, NPS variants modify asthma risk and should be considered in genetic association studies of NPSR1 with asthma and other complex diseases.
Introduction
Neuropeptide S (NPS) affects multiple neuroendocrine, behavioral, and inflammatory responses via its G protein-coupled cell surface receptor NPSR1 (Neuropeptide S Receptor 1) [1–4]. NPSR1 was identified as a susceptibility gene for asthma and related traits by positional cloning and the associations of NPSR1 single nucleotide polymorphisms (SNPs) with asthma have been replicated in ethnically diverse populations [5–12], and marginally supported by a large-scale genome-wide association study (GWAS) [13]. In addition, NPSR1 SNPs have shown genetic associations with other inflammatory phenotypes such as inflammatory bowel disease [14] and rheumatoid arthritis [15, 16]. However, the NPSR1 locus has shown allelic heterogeneity with different markers (tag SNPs, intronic markers, and haplotypes) showing associations depending on the study design and population being studied. We have previously shown that several susceptibility alleles of low-to-moderate-effects in NPSR1 may modify the asthma risk and show epistasis depending on the carrier status for variants in genes belonging to common biological pathways [17]. These effects may not be uncovered by SNP arrays which are suitable for detection of common polymorphisms but cannot detect the effects of less frequent coding mutations and low frequency functional SNPs.

The functional NPSR1 SNP rs324981 (A>T), encoding a substitution of Asn(107)Ile in the putative ligand-binding pocket of NPSR1 [5], has shown associations with neuropsychiatric phenotypes, such as panic disorders [18–20], psychological stress [21], and fear responses [22, 23]. A GWAS on circadian sleep parameters found an association between rs324981 and regular bedtime [24] and another study showed that the same SNP was associated with sleep and rest duration [25]. In cell models, the change of Asn(107) to Ile(107) results in 10-fold increase in NPS-mediated intracellular signaling [26] and changes in genome-wide transcriptional profiles [27]. In addition, the NPSR1 SNP rs324981 has been associated with airway hyperresponsiveness to methacholine in a Chinese population [8]. Non-coding functional SNPs have also been detected in NPSR1, for instance rs2530547 which affects luciferase expression in gene reporter assays and NPSR1 mRNA levels in human leukocytes [27]. By changing the levels of expression in this receptor, they may ultimately also affect signaling, and are hypothesized to affect neuroinflammatory phenotypes [28]. Thereby associations with individual NPSR1 SNPs needs to be evaluated in the context of gene-gene interactions because a combination of functional polymorphisms may ultimately determine receptor properties and/or expression levels [27].

A functional SNP rs4751440 in NPS encodes a Val(6)Leu substitution in the mature NPS peptide that results in lower bioactivity [29]. We hypothesized that the interaction of functional NPS and NPSR1 SNPs might lead to either strong or minimal downstream signaling depending on the genotype combination on both loci. The aims of this study were: 1) To clarify the potential functional crosstalk between NPS and NPSR1 variants; 2) to identify the impact of putative NPS risk alleles on the susceptibility to asthma; and 3) to evaluate potential gene-gene interaction effects (epistasis) between NPS and NPSR1 polymorphisms on asthma.

Results
Biological interaction of NPS and NPSR1 variants can lead to either strong or minimal downstream signaling
NPS is known to activate NPSR1 by increasing cAMP production [30, 31]. To compare the bioactivities of the two NPS variants, we measured the dose-responses of NPSR1-Ile(107) and NPSR1-Asn(107) coding variants to either wildtype NPS-Val(6) or alternative NPS-Leu(6) in a luciferase assay dependent on the activation of a cAMP-response element (CRE). This assay
was used since elevation of the intracellular cAMP levels activates cAMP response element binding protein (CREB) via phosphorylation of protein kinase A (PKA). Activated CREB binds to CRE and induces the expression of downstream target genes of the cAMP/PKA signaling pathway. Because of the low endogenous expression levels of NPSR1 in majority of the available cell lines [26, 29], we first used HEK293 cells with forced NPSR1 expression as a model for ligand-receptor interactions. This approach allowed comparisons between the present and previous studies [26, 29]. HEK293 cells were transiently co-transfected with the two NPSR1 variants along with a CRE-responsive firefly luciferase construct and a construct constitutively expressing Renilla luciferase. Firefly and Renilla luciferase activity was measured 3 h after stimulation with serial dilutions of NPS (10 pM–100 μM). As shown in Fig 1, wildtype NPS—Val(6) peptide stimulated CRE—dependent luciferase activity at 50—fold lower concentrations than the NPS—Leu(6) peptide in NPSR1—Ile(107) cells (pEC 50: 8.4 ± 0.2 and 6.7 ± 0.2, p = 0.004, respectively), and at 15-fold lower concentrations in NPSR1—Asn(107) cells (pEC 50: 6.1 ± 0.3 and 4.9 ± 0.1, p = 0.03, respectively).

The maximum of luciferase activity was ~2-fold in cells transfected with the NPSR1—Ile (107) variant in comparison to the cells transfected with the NPSR1—Asn(107). Thus, the magnitude of NPSR1-induced activation of CRE was markedly different depending on the combination of the NPS and the NPSR1 variants resulting in either strong (NPS-Val(6) and NPSR1—Ile(107)) or minimal (NPS-Leu(6) and NPSR1—Asn(107)) downstream signal transduction.

The activation of CRE results in transcriptional changes of downstream target genes. To examine whether the observed differences in the promoter activity also affected gene expression, we measured the effects of NPS variants on known NPSR1 downstream target genes [27, 32, 33]. NR4A1 (nuclear receptor subfamily 4, group A, member 1), FOS (FBF murine osteosarcoma viral oncogene homolog), and chemokine ligands CXCL2 and CCL20 were selected as they were among the most influenced genes after NPS stimulation and their expression also differed between transcriptome comparisons of HEK293 cells expressing either NPSR1—Ile

Fig 1. NPS variants and CRE luciferase activity. Dose-response curves of NPS-Val(6) and NPS-Leu(6) (10 pM– 100 μM) based on the cAMP response element (CRE) luciferase activity in human embryonic kidney epithelial (HEK293) cells transiently transfected with either NPSR1-Ile(107) or NPSR1-Asn(107) coding variants. One representative experiment is shown. The CRE-driven luciferase activity is expressed in mean arbitrary units ± SEM of triplicates 3 h after NPS stimulation.
(107) or NPSR1-Asn(107) [27]. In the present study, HEK293 cells transiently transfected with either NPSR1-Ile(107) or NPSR1-Asn(107) coding variants were stimulated with 100 nM of either NPS-Val(6) or NPS-Leu(6) for 1, 3, 6, and 24 h, and changes in gene expression were analyzed with RT-PCR. In agreement with the results from the luciferase assay, NPS induced stronger downstream signaling in cells expressing NPSR1-Ile(107) than in cells expressing NPSR1-Asn(107), and wildtype NPS-Val(6) peptide was more potent than the NPS-Leu(6) peptide. mRNA expression of NR4A1, FOS, and CXCL2 was induced 1 h after NPS stimulation whereas the expression of CCL20 was up-regulated at 3 h (Fig 2A).

Altered neuroinflammatory mechanisms have been implicated in allergic airway inflammation [34]. Because NPSR1 is expressed in neuroendocrine tissues [35–37], we used SH-SY5Y neuroblastoma cells of neuroendocrine origin to validate the changes in gene expression observed in HEK293 cells. SH-SY5Y cells stably overexpressing NPSR1-Ile(107) [17, 36] were stimulated with either NPS-Leu(6) or NPS-Val(6) (0.0001–1 μM) for 3 h and the mRNA expression of known downstream target genes in these cells [36] was detected using RT-PCR. As expected, NPS stimulation increased the expression of NR4A1, FOS, EGR1 (early growth response protein 1), and IER3 (immediate early response 3) in SH-SY5Y cells over-expressing NPSR1-Ile(107) in a dose dependent manner (Fig 2B). Wildtype NPS-Val(6) peptide was more potent than the NPS-Leu(6) peptide. These observations validated the results detected in HEK293 cells in an independent cell line.

**NPS rs4751440 encoding Leu(6) is protective for childhood asthma**

Because the SNP rs4751440 (G/C) encoding for NPS-Val(6) and NPS-Leu(6) is common in European and American mixed populations [29], and given its functional effects on NPSR1 signaling in cell assays, we hypothesized that this SNP might influence the genetic risk of diverse disease traits including asthma. The rs4751440 Val(6)Leu and two other NPS SNPs

---

**Fig 2. Real time RT-PCR analysis of NPSR1 downstream target genes.** (A) Time-dependent mRNA expression of NR4A1, FOS, CXCL2, and CCL20 in human embryonic kidney epithelial (HEK293) cells transiently transfected with either NPSR1-Ile(107) or NPSR1-Asn(107) coding variants and stimulated with either NPS-Val(6) or NPS-Leu(6) NPS (100 nM) for 1, 3, 6, and 24 h. (B) Dose-response curves of NR4A1, FOS, IER3, and EGR1 in human SH-SY5Y stable cell line over-expressing NPSR1-Ile(107) stimulated with either NPS-Leu(6) or NPS V6 (0.0001–1 μM) for 3 h. The results are presented as fold-changes in comparison to the unstimulated cells. GAPDH was used as the endogenous reference, and data are expressed as mean of triplicate samples. The error bars represent 95% confidence intervals. In all experiments, results were calculated with the comparative C_t method.

https://doi.org/10.1371/journal.pone.0176568.g002

---
(rs1931704 and rs10830123) were analyzed for associations with physician-diagnosed childhood asthma in the prospective Swedish birth-cohort BAMSE (n = 2033) [38, 39]. The SNPs spanned a region of 11 kb on chromosome 10q26.2 and were in linkage disequilibrium (LD) with each other (Fig 3A). The allele frequencies of the three NPS SNPs in cases and controls and the results of the association tests with asthma are presented in S1 Table. Two NPS SNPs (rs1931704 and rs4751440) in strong linkage disequilibrium (D' = 0.99, r² = 0.69) were significantly associated with physician-diagnosed childhood asthma at age 8 years under dominant (p = 0.01) and additive models (p = 0.03). For both NPS SNPs the effect was driven by a higher frequency of the minor allele in the control group (Fig 3B). These results revealed that the allele C in NPS rs4751440 encoding for Leu(6) is protective for asthma. The association
between NPS variants and asthma was also significant when comparing the haplotype frequencies between asthmatic children and controls with a protective effect driven by the haplotype AGC (p = 0.008) (Table 1). There were no significant associations between NPS SNPs and atopic sensitization (data not shown).

**Gene-gene interactions between NPS and NPSR1 variants**

Based on the effects of the NPS SNP rs4751440 on genetic asthma risk and NPSR1 signaling, we first tested genetic association of 29 NPSR1 SNPs with physician-diagnosed childhood asthma in BAMSE (n = 2033), and then assessed epistasis between NPS and NPSR1. We detected significant association between three NPSR1 SNPs (rs887020, rs2531840 and rs11770777) with asthma (p < 0.05) and confirmed that the functional rs324981 (T>A) encoding for NPSR1-Ile(107) and NPSR1-Asn(107) had no significant main effects at present resolution (S2 Table). The next aim was to investigate if the effects of NPS SNPs (rs1931704, rs10830123 and rs4751440) on the risk of asthma were modified by the carrier status of alleles in the SNP rs324981 (A>T) encoding for NPSR1-Asn(107) and NPSR1-Ile(107), respectively, or by other variants with previous evidence of putative functional effects in the NPSR1 gene. We detected significant interaction between NPS SNP rs10830123 and NPSR1 rs324981 (interaction p value = 0.009). There were also significant interactions between NPS SNP rs10830123 with two additional NPSR1 SNPs (rs323922 and rs324384) in linkage disequilibrium with NPSR1 rs324981 (Fig 4). A second region with significant interactions between NPS and NPSR1 was detected between two SNPs in the NPSR1 promoter (rs2125404 and rs2168890) and NPS SNP rs10830123 (Fig 4) and S3 Table.

We then explored the gene-gene interaction between NPS and NPSR1 SNPs in the MAGIC/ISAAC cohort (n = 1454). NPS and NPSR1 SNPs did not show any significant main effects on asthma risk in this dataset (data not shown). However, there was a significant interaction between NPS rs10830123 and NPSR1 rs17199659 (p = 0.005) (Fig 4 and S3 Table). NPSR1 rs17199659 is in LD (D’ = 0.95, r² = 0.19) with NPSR1 rs324981 encoding for NPSR1-Asn(107) and NPSR1-Ile(107) and with rs324384, both showing significant gene-gene interactions in BAMSE (Fig 4). These results suggested that the epistatic signal with NPS was driven by genetic variants in the proximities of exon 3 and exon 4 in NPSR1.

**Discussion**

Previous studies have shown that some polymorphic variants in the genes encoding NPS and NPSR1 have functional effects in modifying peptide bioactivity or receptor signaling efficacy [26, 29]. However, no study has yet analyzed the functional outcomes of the different combinations of coding NPS and NPSR1 variants upon ligand/receptor interactions. This is of critical relevance, because coding SNPs such as NPS rs4751440 or NPSR1 rs324981 are commonly observed in humans, and cells in any given individual will carry one out of nine alternatives of

---

**Table 1. Haplotype association of NPS polymorphisms with asthma at 8 years.**

| Haplotype | rs1931704 (G>A) | rs10830123 (G>C) | rs4751440 (G>C) | Frequency (controls) | Frequency (asthmatics) | OR 95%CI (p-value) |
|-----------|----------------|-----------------|----------------|---------------------|------------------------|------------------|
| 1  | G  | G  | G  | 0.70 | 0.76 | 1.0 - |
| 2  | A  | G  | C  | 0.14 | 0.10 | 0.71 (0.53–0.94) 0.01 |
| 3  | A  | C  | G  | 0.11 | 0.10 | 0.87 (0.65–1.16) 0.3 |

Global haplotype association p-value = 0.0077

Allele changes are indicated by > and given on the positive chromosomal strand of the Human Reference Assembly.

[https://doi.org/10.1371/journal.pone.0176568.t001](https://doi.org/10.1371/journal.pone.0176568.t001)
genotype combinations at these two loci. We examined the effects of the peptides NPS-Val(6) and NPS-Leu(6) on the signal transduction of NPSR1, expressed as two variants with different signaling efficacy (NPSR1-Ile(107) and NPSR1-Asn(107)). Our results clearly showed that the magnitude of NPSR1 signaling (as determined by reporter gene assays) and expression levels of downstream genes was dependent on the combination of NPS and NPSR1 variants, with the highest induction obtained upon stimulation of NPSR1-Ile(107) overexpressing cells with NPS-Val(6), and the lowest induction obtained with the combination of NPSR1-Asn(107) and NPS-Leu(6). Genetic association analyses further suggested epistasis between NPS and NPSR1 variants with the most significant interactions being centered to the region of NPSR1 rs324981 encoding for NPSR1-Ile(107) and NPSR1-Asn(107).

A key strength of this study is the use of robust in vitro cell assays that allowed us to dissect the functional effects of coding NPS/NPSR1 variants on receptor signaling and downstream gene expression. Our cell assays confirmed that stimulation of cells transfected with either NPSR1·Asn(107) or NPSR-Ile(107) with the wildtype NPS-Val(6), induced CRE activity as described previously [26, 27]. Reinscheid et al. [26] have previously shown that upon stimulation with NPS-Val(6), stable HEK293 cell lines expressing NPSR1·Asn(107) and CRE-luciferase reporter gene displayed an induction of luciferase activity with a mean EC50 of 45 nM, which was roughly 10-fold lower than in this study (428 nM). For NPSR1-Ile (107), the stimulation with NPS-Val(6) produced an increase in reporter gene expression with an EC50 of 0.6 nM, which was 10-fold lower than what we observed (4.8 nM) [26]. The differences could be explained by the ~20-fold lower magnitude of reporter gene induction in transiently transfected cells compared with stable clones [26]. In agreement with our study, the maximum of reporter gene expression in HEK293 cells transiently transfected with NPSR-Ile (107) was ~2-fold higher than in cells expressing NPSR1·Asn(107), indicating an increase in agonist efficacy. Another previous study observed EC50 values of 37 nM and 586 nM for NPS-Val(6)
and NPS-Leu(6), respectively, in CRE-luciferase activity 18 h after stimulation of HEK293 cells transiently transfected with NPSR1-Asn(107) [29]. Overall, our results were in line with these previous observations, and methodological issues, such as differences in NPS incubation time and transfection efficiency, might well explain the differences observed.

Our genetic analyses in the birth cohort BAMSE uncovered the association between NPS rs4751440 and the presence of asthma by 8 years. Another NPS SNP (rs10830123) showed borderline association with asthma, and formed a protective haplotype with NPS rs1931704 and NPS rs4751440. The protective effect of the minor allele C in NPS rs10830123 became significant only in the presence of two copies of rs324981 (TT) encoding NPSR1-Ile(107). In the replication cohort, NPS rs10830123 showed interaction with NPSR1 rs17199659 which is in linkage disequilibrium with rs324981 and rs324384. Due to the LD, NPS rs10830123 can be used as a proxy for the effects of NPS rs4751440 (Fig 4). Although the latter had significant main effects on asthma risk and proved to be functional in the cell assays, a lower frequency of informative GC heterozygotes in the patient group could have influenced the power to detect gene-gene interactions with NPSR1. Indeed, 24% of non-asthmatic children were heterozygous for NPS rs4751440 and there was a low frequency of CC carriers in the cohorts with only 2% of children being homozygous (CC) for NPS-Leu(6). This was in line with previous findings suggesting that 22% of Europeans are heterozygous for NPS rs4751440 [29]. Nevertheless, it is consistent in BAMSE and MAGIC/ISAAC that the most significant interaction was centered to the region of NPSR1 rs324981 encoding for NPSR1-Ile(107) and NPSR1-Asn(107). Altogether, our results supported the role of the NPS/NPSR1 pathway in asthma and the notion of a “combinatory effect”, in which the phenotype is driven by the interaction of several variants of moderate effects that coincide and affect a biological pathway [17].

In BAMSE, the NPS rs10830123 also showed significant interactions with two SNPs located in the upstream region of NPSR1 (rs2125404 and rs2168890). These were in LD with NPSR1 rs2530547 previously found to affect NPSR1 mRNA levels in human leukocytes [27] and with three SNPs affecting NPSR1 mRNA expression in cerebellum (rs2530549, rs2530550, and rs2530566) according to the Genotype-Tissue Expression database (http://gtexportal.org/home/gene/NPSR1). Furthermore, a bioinformatic analysis on the transcription binding sites that are created or destroyed by the five NPSR1 SNPs implicated in the gene-gene interactions with NPS (S3 Table) revealed that the change of cytosine (C) to guanine (G) in NPSR1 rs323922 is predicted to affect the binding site of V$NBRE/NBRE.01 related to the monomers of the nur subfamily of nuclear receptors (NR4A1-3, also known as nur77, nurr1, nor-1, S4 Table).

Previous transcriptome studies in HEK293 cells [32, 33] and SH-SY5Y cells [36] overexpressing NPSR1-Ile(107) revealed downstream target genes with NR4A1 and FOS being among the most affected transcription factors. In our cells assays, the magnitude of the mRNA expression of NR4A1 was clearly dependent on the combination of NPS and NPSR1 variants (Fig 2). NR4A1 is expressed in lymphocytes upon stimulation and is anti-inflammatory [40-42]. NR4A1 has been recently described as a key regulator of catecholamine production by macrophages linking sympathetic stress response and inflammation [43]. The hypothesis of a regulatory loop influenced by particular combinations of NPS/NPSR1 variants is further suggested by the up-regulation of the transcription factor FOS in cells expressing NPSR1-Ile(107) upon stimulation with NPS-Val(6) and the fact that the promoter region of NPSR1 is known to contain FOS binding motifs [28]. The upregulation of NR4A1 and FOS induced by the combination of NPS-Val(6) and NPSR1-Ile(107) is anticipated not only to interact in a feedback loop with their regulatory elements in NPSR1 but also to regulate a number of other target genes including those involved in immune responses. For instance, the levels of serum pro-inflammatory cytokines could be activated by both central and peripheral administration of NPS in
pigs [44], and NPS has shown direct effects on phagocytosis [45] [46] and chemotaxis [47] [48]. Further insights to immune responses are suggested by the upregulation of CXCL2 and CCL20 encoding chemokine receptors ligands (Fig 2).

The findings of significant epistatic signals implicating coding and non-coding variants allowed us to suggest a model in which the divergent biological outcomes driven by coding variants in NPS and NPSR1 do occur at the level of ligand/receptor interactions but also implicate the effects of polymorphic variants in non-coding regions and the cross-talk of regulatory elements in diverse loci (Fig 5). We must emphasize that the sample size analyzed in this study is underpowered to detect epistatic effects. However, the facts that the interaction signals in the two independent cohorts were narrowed to the same gene regions (Fig 4) and a recent meta-analysis on a larger dataset such as GABRIEL [49] confirmed the interaction signals that we originally identified in this population between NPSR1 and RORA [17], suggest that the interactions between NPS and NPSR1 may occur and are detectable at present resolution. Additional studies using larger sample sizes more suitable to test for epistasis are needed to confirm these findings.

In conclusion, our results supported the association of the NPS/NPSR1 pathway with asthma and provided a molecular framework on how the different NPS and NPSR1 variants interact in asthma. This study provides the basis for further investigations analyzing the interacting effects of NPS/NPSR1 variants in many other phenotypes and also support that polymorphic variants in NPS should be taken into account when analyzing the effects of NPSR1 SNPs. Such gene-gene interactions as observed here may dilute or dampen association signals in genetic association studies.

Materials and methods

Ethics statement

All methods were carried out in accordance with relevant guidelines and regulations and the study followed the ethical principles for medical research stated in the Declaration of Helsinki. All of the experimental protocols were approved by the Swedish Regional Ethics Committee at Karolinska Institutet, Stockholm, Sweden in the BAMSE cohort (Dnr: 01–478 and 02–420) and by the Ethic Committee of the Bavarian Medical Council for MAGIC/ISAAC (approval nr. 01218). Written informed consent was obtained from parents/guardians on behalf of all child participants.

Cell culture and NPS stimulations

Human embryonic kidney cells (HEK293) were cultured in MEM+GlutaMAX-1 medium (Gibco/Invitrogen) supplemented with 10% fetal calf serum (FCS) (Biosera), 1% sodium pyruvate, 1% non-essential amino acids and 1% penicillin/streptomycin (Gibco/Invitrogen). Cells were kept at 37°C in a humidified 5% CO2 incubator. The cells were transiently transfected (Lipofectamin™2000 Reagent, Invitrogen, Carlsbad, USA) with equal amounts of pCMV-NPSR1-Ile(107) or NPSR1-Asn(107) [27] in a ratio of 1:2 (DNA:Lipofectamin), and stimulated with NPS 24 h after transfection. The cells were stimulated with either 100 nM NPS-Val(6) (SFRNGVGTGMKKTSFQRAKS) or 100 nM NPS-Leu(6) (SFRNGLGTGMKKTSFQRAKS) (both from Proteogenix, France) for 1, 3, 6, and 24 h. The HEK293 cell line was chosen for ligand-receptor studies because it is a well-established model for addressing numerous questions in basic biology and is easy to transfect and amenable of stringent quantitative assessment.

The stable NPSR1-A-GFP expressing SH-SY5Y cells were engineered and cultured as described before [17]. For gene expression studies, the SH-SY5Y cells over-expressing NPSR1
were seeded at $0.5 \times 10^6$ cells/ml to 6-well plates. After 24 h, fresh cell media was added, and the cells were incubated with a dilution series of either NPS-Val(6) or NPS-Leu(6) (0.0001–10 μM) for 3 h. The changes in gene expression were analyzed with real-time PCR (RT-PCR).
Luciferase assays

For pharmacokinetic studies, HEK293 cells in 24-well plates were co-transfected with 700 ng of NPSR1 cDNA expression vectors specific for different coding variants and 50 ng each of cAMP response element (CRE) Firefly Luciferase reporter vector and CMV Renilla Luciferase reporter plasmid (purchased as pre-formulated mix from SABiosciences, Frederick, MD, USA). The day after transfection the cells were stimulated for 3 h with NPS at various concentrations (range 10 pM - 100 μM) before preparation of total cell lysates. In all reporter assays, Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer’s instructions, in a Microplate Reader Infinite 200 (Tecan, Männedorf, CH). Experiments were performed three times in triplicates, and Firefly Luciferase activity was expressed in arbitrary units relative to the cells transfected with the vector without NPS stimulation, after normalization for transfection efficiency based on values obtained for Renilla Luciferase. The concentration-response curve values for pEC50 and Emax were calculated using nonlinear regression analysis, and the data are presented as means ± SE. Statistical analysis was performed using one-way ANOVA followed by unpaired t-test for comparison between two groups. For the analyses, GraphPad Prism 5.01 (GraphPad Software, San Diego, CA) was used.

Real-time RT-PCR

Total cellular RNA was isolated with the RNAeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription was performed with TaqMan reverse transcription reagents (Applied Biosystems, Rotkreuz, Switzerland) using random hexamer primers according to the manufacturer’s protocol.

The mRNA expression was measured with qRT-PCR using either SYBR Green (for NR4A1, FOS, IER3, and EGR1, the primer sequences are given in S5 Table) or TaqMAN assay (Hs0061975 for CXCL2 Hs0061975, Hs01011368 for CCL20, Hs01036497 for NPSR1 and Pre-Developed TaqMAN Assay Reagents, Part No. 4310884 for GAPDH; Applied Biosystems). The PCR assays were performed in a total volume of 10 μl, using 7500 Fast Real-Time PCR system (Applied Biosystems) with the following reaction conditions: 50˚C for 2 min and 94˚C for 10 min; followed by 45 cycles of 92˚C for 14 s and 1 min at 60˚C. A dissociation stage was added to the SYBR Green reactions to confirm primer specificity. Results are shown as relative expression compared with unstimulated cells and GAPDH (Applied Biosystems) was used as an endogenous control. Samples were normalized to GAPDH (in SH-SY5Y cells) or to GAPDH and NPSR1 in order to control for the efficiency of the transient transfections (in HEK293 cells). The variation in NPSR1 expression (Ct values) between cells transfected with the NPSR1-Asn(107) and NPSR1-Ile(107) was within one cycle. Expression levels of mRNA in each sample were determined by the comparative C_T method of relative quantification, and expressed in fold-changes relative to the chosen reference sample.

Study populations

Genetic association analyses were conducted in the prospective Swedish birth-cohort BAMSE (Children Allergy Milieu Stockholm an Epidemiological study), which is an unselected, population-based Swedish birth cohort originally designed to assess risk factors for allergic diseases in childhood. This prospective study of 4,089 children has been described in detail elsewhere [38, 39]. At age 8, all children were invited to clinical testing and blood samples were obtained. After exclusion of samples with too little blood, incomplete questionnaire data, or lack of parental consent to genetic analysis there were 2033 samples with DNA extracted for genetic studies (of which 262 were asthmatics). All samples were analyzed coded. The study was
approved by the Regional Ethical Committee of Karolinska Institutet, Stockholm, Sweden. Written informed consent was obtained from the parents and/or legal guardians.

Replication studies were carried out in 1454 children from the Multicenter Asthma Genetic in Childhood (MAGIC) study (mean age 11 y) and the cross sectional International Study of Asthma and Allergies in Childhood phase II (ISAAC II) study (age 9–11 y) [50–52]. From both populations, all samples which had been part of the first GWAS on asthma [50] and for which we had imputation data available were selected for this study. After quality control (QC), 1,454 samples (763 asthmatics and 683 controls) remained for analysis. All study methods were approved by the local ethics committees and written informed consent was obtained from all parents of children included in this study. To control for population stratification, all children were of German descent. Considering that previous studies have detected only marginal genetic differences between Swedes and Germans, and that GWAS data supported that within Europe, Germans and Swedes are most closely related [53], it can be assumed that the Swedish BAMSE and the German ISAAC/MAGICS were comparable.

Phenotype assessment

Information on the clinical outcomes was obtained from questionnaires filled out by the parents, except for atopic sensitization which was assessed from plasma samples. In BAMSE, Asthmaever up to 8 years was defined as a physician-diagnosed asthma between 3 mo after birth and up to 8 y of age [54]. Atopic sensitization was considered present if a child had levels of allergen-specific IgE >0.35 kU/L to Phadiatop, a mixture of cat, dog, horse, birch, timothy, mugwort, Dermatophagoidespteronyssinus, and Cladosporium allergens at 8 y of age (ImmunoCAP, Thermo Fisher Scientific, Phadia AB, Uppsala, Sweden).

In MAGIC, the assessed variables included asthma and allergy, which were diagnosed by a pediatric pulmonologist according to clinical guidelines and objective measures such as lung function tests, clinical examination, and allergy testing [51, 55]. In ISAAC II, children were classified as having asthma if parents reported a physician’s diagnosis of asthma at least once, or of spastic or asthmatic bronchitis more than once in self-administered questionnaires [56, 57]. The populations of the Swedish BAMSE and the German ISAAC/MAGICS are assumed to be comparable because in both, the definition of the phenotype “asthma” was based on a physician-diagnosis and the age range of the children was comparable (8 years in BAMSE vs. 10 years in ISAAC/MAGICS) [58].

SNP selection, genotyping and quality control

In BAMSE the NPS and NPSRI polymorphisms were genotyped by using the iPLEX chemistry on the SEQUENOM platform at the Mutation Analysis Facility (Karolinska Institutet), with the exception of rs4751440 which was genotyped by a TaqMan SNP Genotyping Assay in an ABI Prism 7500 Fast Sequence Detection System (Applied Biosystems) according to manufacturer’s instructions. Primers for multiplex PCR and extension reactions were designed by the SpectroDesigner software (Sequenom GmbH, San Diego, CA, USA) and are available on request. Each assay was validated using 24 unrelated Caucasians and 3 CEPH DNA samples as well as 14 trios from the CEU population. Success rate for genotyping was 98.8%. In the MAGIC/ISAAC study, NPS and NPSRI SNPs were genotyped by the Illumina Sentrix Human-Hap300 BeadChip as previously described [50]. The NPS gene spans a region of 3.3 kb on chromosome 10q26.2 whereas the NPSRI gene spans over ~220 kb of genomic DNA on chromosome 7p14. The SNPs included in this study were selected based on their effects on protein function (e.g. variants encoding for NPS-Val(6)Leu and NPSRI-Asn(107)Ile); previous reports of association with asthma in children from BAMSE [6, 17] and other populations [5–12]; and
by their functional [27] and tagging properties [17, 19, 28]. We analyzed 3 NPS SNPs (rs1931704, rs10830123 and rs4751440 Val(6)Leu), 29 NPSR1 SNPs in the BAMSE cohort [17, 19], and 23 NPSR1 SNPs in MAGIC/ISAAC [50]. The discrepancy in the number of NPSR1 SNPs was due to the fact that some SNPs genotyped in BAMSE were not present in the array. Genotype frequencies for all SNPs agreed with the expectations under Hardy-Weinberg equilibrium.

Genetic association tests

Genetic association tests were conducted using Plink (version 1.07, http://pngu.mgh.harvard.edu/purcell/plink) using the commands—assoc and—model. The comparison of allele frequencies between cases and controls were done by $\chi^2$ and Fisher’s exact test. Full model associations were evaluated using the Cochran-Armitage trend test, and genotypic, dominant and recessive models. The genotypic and dominant/recessive tests were only conducted if there was a minimum number of five observations per cell either in the 2-by-3 or 2-by-2 tables. Since we tested 32 individual SNPs it was expected at least 1.6 SNPs to be significant ($p < 0.05$) due to chance. Epistasis was evaluated using the—epistasis command in PLINK. All pairwise SNP combinations were tested in the case-control datasets. Allelic by allelic epistasis between NPS and NPSR1 SNPs were calculated by logistic regression. The allele dosage of each SNP (A and B) was modeled in the form of $Y = \beta_0 + \beta_1A + \beta_2B + \beta_3AB + e$ and the test for interaction based on the coefficient $\beta_3$. In the equation, $Y$ represents the presence of asthma as a function of the intercept ($\beta_0$) and the coefficients of the different alleles, and $e$ the residual error.

Supporting information

S1 Table. Genetic association of NPS polymorphisms with asthma at age 8 years in the BAMSE cohort. (DOCX)

S2 Table. Genetic association of NPSR1 polymorphisms with asthma at age 8 years in the BAMSE cohort. (XLSX)

S3 Table. Interactions between NPS and NPSR1 on the risk of asthma under the multiplicative model. (DOCX)

S4 Table. Predicted changes in transcription factor binding sites encoded by the SNPs implicated in the epistasis between NPS and NPSR1 as determined by the Genomatix Software Suite. (XLS)

S5 Table. Primers used for qPCR analysis in the human cell lines and mice experiments. (DOCX)

Acknowledgments

The authors thank all the children and their parents who participated in the BAMSE study. Christina Orsmark-Pietras, Francesca Anedda, Juri Olkkonen, Tinja Kanerva, Auli Saarinen, and the Mutation Analysis core Facility (MAF) at Karolinska Institutet are acknowledged for their help and skillful laboratory work. We thank Annika Scheynius and Göran Pershagen for support and discussions.
Author Contributions

Conceptualization: NA VP JK.
Data curation: NA SKM VG CS EM MK VP.
Formal analysis: NA SKM VG CS EM VP.
Funding acquisition: MK JK VP.
Investigation: NA SE CS EM VP.
Methodology: NA JK VP.
Project administration: VP.
Resources: NA SE SKM CS MDA EM MK JK VP.
Software: SKM VG.
Supervision: JK VP.
Validation: MK JK VP.
Visualization: NA JK VP.
Writing – original draft: NA VP.
Writing – review & editing: NA SE SKM VG CS MDA EM MK JK VP.

References

1. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, et al. Neuropeptide S: a neuro-peptide promoting arousal and anxiolytic-like effects. Neuron. 2004 Aug 19; 43(4):487–97. https://doi.org/10.1016/j.neuron.2004.08.005 PMID: 15312648
2. Okamura N, Reinscheid RK. Neuropeptide S: a novel modulator of stress and arousal. Stress. 2007 Aug; 10(3):221–6. https://doi.org/10.1080/10253890701248673 PMID: 17613937
3. Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo G. Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Medicinal research reviews. 2010 Sep; 30(5):751–77. https://doi.org/10.1002/med.20180 PMID: 19824051
4. Pape HC, Jungling K, Seidenbecher T, Lesting J, Reinscheid RK. Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology. 2010 Jan; 58(1):29–34. https://doi.org/10.1016/j.neuropharm.2009.06.001 PMID: 19523478
5. Laitinen T, Polvi A, Rydman P, Vendelin J, Pulkkinen V, Salmikangas P, et al. Characterization of a common susceptibility locus for asthma-related traits. Science. 2004 Apr 9; 304(5668):300–4. https://doi.org/10.1126/science.1090010 PMID: 15073379
6. Melen E, Bruce S, Doekes G, Kabesch M, Laitinen T, Lauener R, et al. Haplotypes of G protein-coupled receptor 154 are associated with childhood allergy and asthma. American journal of respiratory and critical care medicine. 2005 May 15; 171(10):1089–95. https://doi.org/10.1164/rccm.200410-1317OC PMID: 15710598
7. Kormann MS, Carr D, Klopp N, Ilig T, Leupold W, Fritsch C, et al. G-Protein-coupled receptor polymorphisms are associated with asthma in a large German population. American journal of respiratory and critical care medicine. 2005 Jun 15; 171(12):1358–62. https://doi.org/10.1164/rccm.200410-1312OC PMID: 15764725
8. Feng Y, Hong X, Wang L, Jiang S, Chen C, Wang B, et al. G protein-coupled receptor 154 gene polymorphism is associated with airway hyperresponsiveness to methacholine in a Chinese population. The Journal of allergy and clinical immunology. 2006 Mar; 117(3):612–7. https://doi.org/10.1016/j.jaci.2005.11.045 PMID: 16522461
9. Malerba G, Lindgren CM, Xumerle L, Kiviluoma P, Trabetti E, Laitinen T, et al. Chromosome 7p linkage and GPR154 gene association in Italian families with allergic asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2007 Jan; 37(1):83–9.
10. Hersh CP, Raby BA, Soto-Quiros ME, Murphy AJ, Avila L, Lasky-Su J, et al. Comprehensive testing of positionally cloned asthma genes in two populations. American journal of respiratory and critical care medicine. 2007 Nov 1; 176(9):849–57. https://doi.org/10.1164/rccm.200704-592OC PMID: 17702965

11. Vergara C, Jimenez S, Acevedo N, Martinez B, Mercado D, Gusmao L, et al. Association of G-protein-coupled receptor 154 with asthma and total IgE in a population of the Caribbean coast of Colombia. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2009 Oct; 39(10):1558–68.

12. Castro-Giner F, de Cid R, Gonzalez JR, Jarvis D, Heinrich J, Janson C, et al. Positionally cloned genes converging evidence for a role in panic disorder. Molecular psychiatry. 2011 Sep; 16(9):938–48. https://doi.org/10.1038/mp.2010.81 PMID: 20705147

13. D’Amato M, Zucchelli M, Seddighzadeh M, Anedda F, Lindblad S, Kere J, et al. Analysis of neuropeptide S receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2007 Sep; 133(3):808–17. https://doi.org/10.1053/j.gastro.2007.06.012 PMID: 17854952

14. Robledo G, Gonzalez-Gay MA, Fernandez-Gutierrez B, Lamas JR, Balsa A, Pascual-Salcedo D, et al. Neuropeptide S receptor gene (NPSR1) polymorphism is associated with reduced risk of rheumatoid arthritis. The Journal of rheumatology. 2012 Jun; 39(6):1166–70. https://doi.org/10.3899/jrhave.111205 PMID: 22548985

15. Acevedo N, Saaf A, Soderhall C, Melen E, Ezer S, Pirkola S, Gratacos M, et al. Interaction between retinoid acid receptor-related orphan receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma. PloS one. 2013; 8(4):e60111. https://doi.org/10.1371/journal.pone.0060111 PMID: 23565190

16. Okamura N, Hashimoto K, Iyo M, Shimizu E, Dempfle A, Friedel S, et al. Gender-specific association of a functional coding polymorphism in the Neuropeptide S receptor gene with panic disorder but not with schizophrenia or attention-deficit/hyperactivity disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2007 Oct 1; 31(7):1444–8.

17. Donner J, Haapakoski R, Ezer S, Melen E, Pirkola S, Gratacos M, et al. Assessment of the neuropeptide S system in anxiety disorders. Biological psychiatry. 2010 Sep 1; 68(5):474–83. https://doi.org/10.1016/j.biopsych.2010.05.039 PMID: 20705147

18. Domshike K, Reif A, Weber H, Richter J, Hohoff C, Ohrmann P, et al. Neuropeptide S receptor gene—converging evidence for a role in panic disorder. Molecular psychiatry. 2011 Sep; 16(9):938–48. https://doi.org/10.1038/mp.2010.81 PMID: 20963625

19. Kurmsta R, Chen FS, Pape HC, Heinrichs M. Neuropeptide S receptor gene is associated with cortisol responses to social stress in humans. Biological psychiatry. 2013 May; 92(3):304–7. https://doi.org/10.1016/j.biopsych.2012.07.018 PMID: 23468585

20. Jungling K, Seidenbecher T, Sosulina L, Letzring J, Sangha S, Clark SD, et al. Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron. 2008 Jul 31; 59(2):288–310. https://doi.org/10.1016/j.neuron.2008.07.002 PMID: 18667157

21. Raczka KA, Gartmann N, Mechias ML, Reif A, Buchel C, Deckert J, et al. A neuropeptide S receptor variant associated with overinterpretation of fear reactions: a potential neurogenetic basis for catastrophizing. Molecular psychiatry. 2010 Nov; 15(11):1045, 67–74. https://doi.org/10.1038/mp.2010.79 PMID: 20628342

22. Gottlieb DJ, O’Connor GT, Wilk JB. Genome-wide association of sleep and circadian phenotypes. BMC medical genetics. 2007; 8 Suppl 1:S9.

23. Spada J, Sander C, Burkhartd R, Hantsch M, Mergrl R, Scholz M, et al. Genetic association of objective sleep phenotypes with a functional polymorphism in the neuropeptide S receptor gene. PloS one. 2014; 9(6):e98789. https://doi.org/10.1371/journal.pone.0098789 PMID: 24896286

24. Reinscheid RK, Xu YL, Okamura N, Zeng J, Chung S, Pal R, et al. Pharmacological characterization of human and murine neuropeptide s receptor variants. The Journal of pharmacology and experimental therapeutics. 2005 Dec; 315(3):1338–45. https://doi.org/10.1124/jpet.105.083427 PMID: 16144971

25. Anedda F, Zucchelli M, Schepis D, Hellquist A, Corrado L, D'Alfonso S, et al. Multiple polymorphisms affect expression and function of the neuropeptide S receptor (NPSR1). PloS one. 2011; 6(12):e29523. https://doi.org/10.1371/journal.pone.0029523 PMID: 22216392

26. Henstrohm M, Zucchelli M, Soderhall C, Bergstrom A, Kere J, Melen E, et al. NPSR1 polymorphisms influence recurrent abdominal pain in children: a population-based study. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society. 2014 Oct; 26(10):1417–25.
29. Deng C, He X, Hsueh AJ. A single-nucleotide polymorphism of human neuropeptide S gene originated from Europe shows decreased bioactivity. PLoS one. 2013; 8(12):e83009. https://doi.org/10.1371/journal.pone.0083009 PMID: 24386135

30. Erdmann F, Kugler S, Blaesse P, Lange MD, Skryabin BV, Pape HC, et al. Neuronal expression of the human neuropeptide S receptor NPSR1 identifies NPS-induced calcium signaling pathways. PLoS one. 2015; 10(2):e0117319. https://doi.org/10.1371/journal.pone.0117319 PMID: 25714705

31. Liao Y, Lu B, Ma Q, Wu G, Lai X, Zang J, et al. Human Neuropeptide S Receptor Is Activated via a Galphalphaq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues. The Journal of biological chemistry. 2016 Apr 01; 291(14):7505–16. https://doi.org/10.1074/jbc.M115.704122 PMID: 26865629

32. Vendelin J, Bruce S, Holopainen P, Pulikkinen V, Ryttila P, Pirskanen A, et al. Downstream target genes of the neuropeptide S-NPSR1 pathway. Human molecular genetics. 2006 Oct 1; 15(19):2923–35. https://doi.org/10.1093/hmg/ddi234 PMID: 16926187

33. Pietras CO, Vendelin J, Anedda F, Bruce S, Adner M, Sundman L, et al. The asthma candidate gene NPSR1 mediates isoform specific downstream signalling. BMC pulmonary medicine. 2011; 11:39. https://doi.org/10.1186/1471-2466-11-39 PMID: 21707994

34. Talbot S, Abdulnoor RE, Burkett PR, Lee S, Cronin SJ, Pascal MA, et al. Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation. Neuron. 2015 Jul 15; 87(2):341–54. https://doi.org/10.1016/j.neuron.2015.06.007 PMID: 26119026

35. Sundman L, Saarialho-Kere U, Vendelin J, Lindfors K, Assadi G, Kaukinen K, et al. Neuropeptide S receptor 1 expression in the intestine and skin—putative role in peptide hormone secretion. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society. 2010 Jan; 22(1):79–87, e30.

36. Pulikkinen V, Ezer S, Sundman L, Hagstrom J, Remes S, Soderhall C, et al. Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. Virchows Archiv: an international journal of pathology. 2014 Aug; 465(2):173–83.

37. Hamsten C, Haggmark A, Grundstrom J, Mikus M, Lindskog C, Konradsen JR, et al. Protein profiles of the neuropeptide S-NPSR1 pathway. Human molecular genetics. 2006 Oct 1; 15(19):2923–35. https://doi.org/10.1093/hmg/ddl090 PMID: 16600990

38. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2002; 13 Suppl 15:11–3.

39. Kull I, Melen E, Alm J, Hallberg J, Svartengren M, van Hage M, et al. Breast-feeding in relation to asthma, lung function, and sensitization in young schoolchildren. The Journal of allergy and clinical immunology. 2010 May 15; 15(10):1667–79. https://doi.org/10.1093/hmg/ddl090 PMID: 21725321

40. Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nature immunology. 2011 Aug; 12(8):778–85. https://doi.org/10.1038/ni.2063 PMID: 21725321

41. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Hertley E, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circulation research. 2012 Feb 3; 110(3):416–27. https://doi.org/10.1161/CIRCRESAHA.111.253377 PMID: 22194622

42. Murphy EP, Crean D. Molecular Interactions between NR4A Orphan Nuclear Receptors and NF-kappaB Are Required for Appropriate Inflammatory Responses and Immune Cell Homeostasis. Biomolecules. 2015; 5(3):1302–18. https://doi.org/10.3390/biom5031302 PMID: 26131976

43. Shaked I, Hanna RN, Shaked H, Chodaczek G, Nowyhed HN, Tweet G, et al. Transcription factor N4a1 couples sympathetic and inflammatory cues in CNS-recruited macrophages to limit neuroinflammation. Nature immunology. 2015 Dec; 16(12):1226–34. https://doi.org/10.1038/ni.3321 PMID: 26523867

44. Yao Y, Su J, Zhang F, Lei Z. Effects of central and peripheral administration of neuropeptide S on the level of serum proinflammatory cytokines in pigs. Neuroimmunomodulation. 2014; 21(1):45–51. https://doi.org/10.1055/s-0035-1577777 PMID: 24216974

45. Yao Y, Su J, Yang G, Zhang G, Lei Z, Zhang F, et al. Effects of neuropeptide S on the proliferation of splenic lymphocytes, phagocytosis, and proinflammatory cytokine production of pulmonary alveolar macrophages in the pig. Peptides. 2011 Jan; 32(1):118–24. https://doi.org/10.1016/j.peptides.2010.09.021 PMID: 20933561

46. Pulikkinen V, Majuri ML, Wang G, Holopainen P, Obase Y, Vendelin J, et al. Neuropeptide S and G protein-coupled receptor 154 modulate macrophage immune responses. Human molecular genetics. 2006 May 15; 15(10):1667–79. https://doi.org/10.1093/hmg/dd0990 PMID: 16600990

47. Filareo M, Novi C, Ruggieri V, Genedani S, Alboni S, Malagoli D, et al. Neuropeptide S stimulates human monocyte chemotaxis via NPS receptor activation. Peptides. 2013 Jan; 39:16–20. https://doi.org/10.1016/j.peptides.2012.10.013 PMID: 23142110
48. Ilmarinen P, James A, Moilanen E, Pulkkinen V, Daham K, Saarelainen S, et al. Enhanced expression of neuropeptide S (NPS) receptor in eosinophils from severe asthmatics and subjects with total IgE above 100IU/ml. Peptides. 2014 Jan; 51:100–9. https://doi.org/10.1016/j.peptides.2013.10.030 PMID: 24239856

49. Murk W, Bracken MB, DeWan AT. Confronting the missing epistasis problem: on the reproducibility of gene-gene interactions. Human genetics. 2015 Aug; 134(8):837–49. https://doi.org/10.1007/s00439-015-1564-3 PMID: 25998948

50. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007 Jul 26; 448(7152):470–3. https://doi.org/10.1038/nature06014 PMID: 17611496

51. Potaczek DP, Michel S, Sharma V, Zeilinger S, Vogelberg C, von Berg A, et al. Different FCER1A polymorphisms influence IgE levels in asthmatics and non-asthmatics. Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology. 2013 Aug; 24(5):441–9.

52. Schieck M, Michel S, Suttner K, Illig T, Zeilinger S, Franke A, et al. Genetic variation in TH17 pathway genes, childhood asthma, and total serum IgE levels. The Journal of allergy and clinical immunology. 2014 Mar; 133(3):888–91. https://doi.org/10.1016/j.jaci.2013.08.048 PMID: 24184148

53. Heath SC, Gut IG, Brennan P, McKay JD, Bencko V, Fabianova E, et al. Investigation of the fine structure of European populations with applications to disease association studies. European journal of human genetics: EJHG. 2008 Dec; 16(12):1413–29. https://doi.org/10.1038/ejhg.2008.210 PMID: 19020537

54. Melen E, Granell R, Kogevinas M, Strachan D, Gonzalez JR, Wjst M, et al. Genome-wide association study of body mass index in 23,000 individuals with and without asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2013 Apr; 43(4):463–74.

55. Michels S, Liang L, Depner M, Klopp N, Ruether A, Kumar A, et al. Unifying candidate gene and GWAS Approaches in Asthma. PloS one. 2010; 5(11):e13894. https://doi.org/10.1371/journal.pone.0013894 PMID: 21103062

56. Weiland SK, von Mutius E, Hirsch T, Duhme H, Fritzsch C, Werner B, et al. Prevalence of respiratory and atopic disorders among children in the East and West of Germany five years after unification. The European respiratory journal. 1999 Oct; 14(4):862–70. PMID: 10573234

57. von Mutius E, Weiland SK, Fritzsch C, Duhme H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. Lancet. 1998 Mar 21; 351(906):862–6. https://doi.org/10.1016/S0140-6736(97)10100-3 PMID: 9525363

58. Depner M, Fuchs O, Genuenit J, Karvonen AM, Hyvarinen A, Kaulek V, et al. Clinical and epidemiologic phenotypes of childhood asthma. American journal of respiratory and critical care medicine. 2014 Jan 15; 189(2):129–38. https://doi.org/10.1164/rccm.201307-1199OC PMID: 24293801